ArticleCancer science2025
DHCR7 Promotes Liver Metastasis of Pancreatic Cancer Through PI3K-Akt Signaling Pathway.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GALNT6-glycosylated LRG1 mediates the interaction between M2 macrophages and pancreatic cancer cells by activating CCR1/PI3K/AKT axis.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Pancreatic cancer (PC) is associated with dismal clinical outcomes, largely due to the high prevalence of liver metastasis (LM) at diagnosis or post-resection. Despite its clinical significance, the molecular drivers of LM in PC remain poorly characterized, and few validated biomarkers or therapeutic targets are currently available. Our study identifies 7-dehydrocholesterol reductase (DHCR7), a terminal enzyme in cholesterol biosynthesis, as significantly upregulated in PC tissues and closely correlated with LM progression. In vitro experiments demonstrated that DHCR7 enhances the proliferation, invasion, and migration ability in PC cells, and in vivo experiments demonstrated that DHCR7 promotes LM of PC. The mechanism of DHCR7 promoting LM may be mediated by elevating cholesterol synthesis of PC cells and then activating the PI3K-Akt signaling pathway. Taken together, our findings uncover a novel molecular mechanism underlying LM in PC and highlight DHCR7 as a possible predictive biomarker or interventional target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.